Efavirenz Outperforms Boosted Atazanavir among Treatment-Naive HIV-1-Infected Persons in Routine Clinical Care

Toshibumi Taniguchi MD
Jessica R. Grubb MD
Diana Nurutdinova MD
Nur F. Önen MD
Enbal Shacham PhD
Michael Donovan BS
Edgar Turner Overton MD

Open link

Publication date

March 2013

DOI

10.1177/1545109712467057

Publisher

SAGE Publications

Journal

Journal of the International Association of Providers of AIDS Care (JIAPAC)

Abstract

Background: Effectiveness of antiretroviral therapy (ART) in a routine clinical care may result different from the clinical trials. We assessed the virologic outcomes in treatment-naive persons who received either efavirenz (EFV) or atazanavir/ritonavir (ATV/r) with a backbone of tenofovir/emtricitabine (TDF/FTC) as their combination ART (cART). Methods: This was a retrospective cohort study conducted at the Washington University HIV Outpatient Clinic from January 2004 to June 2009. Predictors of virologic suppression (HIV RNA level <400 copies/mL) by week 48 were assessed by multivariate Cox proportional hazards regression models. Results: Of 324 persons, 221(68%) received EFV and 103 (32%) received ATV/r. Persons on EFV had 1.4-fold incr...